Case Report

Metastatic prostate cancer presenting as incidental pelvic lymphadenopathy – a report of three cases with literature review

Seyan M.T. Dattani\textsuperscript{a}, Maria Luiza Yamada\textsuperscript{b}, Nilu Malpani Dhoot, FRCR\textsuperscript{b,*}, Gamal Ghazala, FRCR\textsuperscript{b}, Adam Levene, FRCP\textsuperscript{c}, Ramkumar Somsundaram, FRCR\textsuperscript{b}

\textsuperscript{a} Biology Student, University College London, PACS Assistant, Luton and Dunstable University Hospital, Luton, UK
\textsuperscript{b} Department of Radiology, Luton and Dunstable University Hospital. Luton-LU4 0DZ, UK
\textsuperscript{c} Cellular Pathology, Luton and Dunstable University Hospital, Luton, UK

A B S T R A C T

The presence of metastatic lymph nodes is a poor prognostic factor in patients with prostate cancer. Currently, there is no national prostate cancer screening program through prostate-specific antigen testing and the benefits of initiating such a scheme have not yet been proven. However, an informed choice program is in place, on request, for men over the age of 50, following discussion with a healthcare professional and an assessment of the potential benefits. This test is also available to men presenting with lower urinary tract symptoms. We report three cases in men who were imaged for non-specific reasons and found to have pelvic lymphadenopathy. The patients reported no urinary symptoms and all were subsequently diagnosed as metastases from a prostatic primary. As this diagnosis was not considered at an earlier stage, there was a delay in initiating appropriate treatments.

\(^{\star}\) Competing Interests: None

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Malignant cells from the early stages of advanced prostate cancer (PCa) often migrate locally, invading blood vessels and, potentially, spreading to other sites. Bones are the most commonly recognized site in metastatic prostate cancer and the presence of sclerotic lesions in the skeleton on imaging will alert the reporter to a diagnosis of disseminated prostate malignancy \([1]\).

Metastatic lymph nodes comprise the second most common site for prostate cancer, after bone \([2]\). It is also a poor prognostic factor for the disease, and survival rates are significantly reduced in patients showing large lymph nodes \([3]\). Previous studies have demonstrated that the most common nodes involved are those in the pelvis and retroperitoneum \([4]\). Currently, no screening programme is in place in the UK, however, prostate-specific antigen (PSA) tests are offered in specific situations including in men over the age of 50 or patients presenting with worrying lower
urinary tract symptoms or bone pain suggesting metastatic disease [5].

There are several differentials for incidental enlarged pelvic nodes [6]. In elderly male patients who are found to have enlarged pelvic nodes, however, PSA correlation should be considered. We present a series of three cases where pelvic lymphadenopathy was found on imaging in patients with no prostate-specific symptoms. Upon further investigation, these nodes were revealed to be metastatic prostate tumours. As the diagnosis was not considered at the outset, there was a delay in commencing treatment.

**Case presentation**

**Case 1**

A 74 year-old-man was under annual surveillance for an abdominal aortic aneurysm. A CT Aortic Angiogram was performed in 2020 (Fig. 1) and displayed enlarged lymph nodes in the right external iliac lymph node, right common iliac lymph node and aortocaval regions. The largest of these measured 23mm. Upon comparison with previous studies, it was appar-ent that these lymph nodes had been present for the previous 2 years - albeit smaller - but were not present in 2017. The patient did not exhibit any urinary symptoms at the time. He was discussed at a haematology MDT and a contrast-enhanced scan of the thorax, abdomen and pelvis was arranged. Some-time after 6 months, the patient developed mild symptoms of increased urinary frequency and slow urine flow with no reported haematuria. Clinical examination confirmed a mildly enlarged nodular prostate gland.

A multidisciplinary opinion was taken and subsequent re-examination of the patient's angiograms revealed multiple sclerotic bone lesions and enlarged nodes (Fig. 1). The prostate gland was not enlarged on any of the scans. Concerned about the possibility of metastasis from primary prostate cancer led to the measurement of patient's PSA concentration, and this was elevated at 737ng/m. The urology team then reviewed the patient and a whole-body bone scan was performed, which revealed multiple metastases in the spine, scapula and femur (Fig. 1).

Upon reviewing the CT scans, it was revealed that small bony metastases had been present in the scan done in 2020, but were not reported at the time of the original report. This individual was referred to a joint uro-oncology clinic and commenced on Bicalutamide and Goserelin.
Case 2

In 2015, a 71-year-old patient presented with a history of progressive symmetrical lower limb sensory disturbance in a stocking distribution. Initial haematins revealed low serum folate. A diagnosis of sensory-motor polyneuropathy was made. He was treated with Pregabalin and his symptoms stabilized.

Four years later, the patient’s condition deteriorated, with neuropathy extending to the knees. He was referred to a peripheral nerve disorder specialist and, upon examination, there was diminished vibration sensation in his feet and distal loss of pinprick sensation in his lower limbs. The Pregabalin dosage was increased and a lumbosacral MRI scan was performed to exclude lumbar stenosis as a cause for the patient’s deteriorating symptoms. He showed degenerative changes in the spine but no significant canal narrowing. However, the axial sequences revealed the presence of an enlarged lymph node along left common iliac artery measuring 14mm (Fig. 2). A CT scan of the thorax, abdomen and pelvis was subsequently performed but this did not reveal any other lymphadenopathy or primary malignancy.

The patient developed urinary symptoms of dribbling and hesitancy after about a year. The prostate was found to be nodular and bulky on clinical examination. In early 2021, an MRI of the Pelvis and Prostate (Fig. 2) was performed which demonstrated the presence of a locally infiltrative mass lesion extending from the apex to the base of the prostate measuring 46 × 34 × 66 mm. The lesion had extended beyond the prostate capsule on the left side with imaging evidence of infiltration into the inferior bladder wall. In addition, there were several focal sclerotic lesions each measuring around 10 mm in the right femoral head, which were not characterized on the MRI. The PSA concentration was mildly elevated at 28 ng/mL. A staging CT scan was subsequently performed and showed an increase in the size of the previously seen node and new retroperitoneal lymph nodes. A prostate biopsy was performed and confirmed an acinar adenocarcinoma of prostate origin (Fig. 2).

Case 3

A 76 year-old-man first reported a left-sided sore throat and a left-sided supraclavicular lump in 2020. A series of investigations were performed, including a CT Neck, Thorax, Abdomen and Pelvis, (Fig. 3) which showed bilaterally enlarged lymph nodes in the neck, an enlarged right subpleural node, common iliac nodes and an enlarged right pelvic side wall node.
The pelvic node measured 15mm on the short axis. An imaging diagnosis of lymphoma was considered likely. The patient declined the offer of a biopsy due to the ongoing COVID-19 pandemic. He displayed no urinary symptoms.

In 2021, the patient re-presented with a reported weight loss of 3 kg and had developed mild signs of nocturia and hesitancy. He was referred to the head and neck oncology team and a PSA was requested but he was still reluctant to have a biopsy. His PSA concentration was significantly elevated at 526 ng/mL. An MRI Pelvis and Prostate (Fig. 3) was subsequently performed and showed a 21cc prostate, with bilateral nodal enlargement. A whole-body bone scan was negative for metastasis. A lymph node core biopsy performed later was consistent with metastatic prostatic adenocarcinoma (Fig. 3).

**Discussion**

PCa is the most common cancer in men with approximately 52,300 new cases diagnosed in the UK every year. The incidence rate is highest in males in their late 70s [7]. The cancer is usually diagnosed early through symptoms and routine PSA measurements but, in some cases, patients may not present with symptoms [7]. The presence of lymph node metastases is a poor prognostic sign and mortality rates are often higher in those with nodal involvement [8].

PCa spread can be local, following extra-capsular spread to adjacent structures such as the seminal vesicles or the bladder [9]. Lymphatic dissemination results in nodal involvement, usually commencing in the pelvic nodes and spreading cranially to involve retroperitoneal nodes at a later stage [9,10]. PCa mainly spreads through the lateral route, to the obturator nodes (the medial chain of the external iliac), then to the middle and lateral chains of the external iliac nodes. The second most common route is the internal iliac (hypogastric) route. Drainage can also occur along an anterior route, via nodes located anterior to the urinary bladder and a presacral route anterior to the sacrum and the coccyx [9–11]. Haematogenous spread is the cause of bone, lung and hepatic deposits [9].

Saeter et al. [12] studied 47 patients with prostate carcinoma, who at the time of diagnosis had involved lymph nodes. They also reported that the supraclavicular fossa was the most common site of extra-skeletal non-regional lymphatic spread and that the survival rates in these patients were similar to those who presented with skeletal metastases. Both groups of patients will respond similarly to hormonal therapy.

Platania et al. [13] reported a case of prostate cancer presenting with enlarged left supraclavicular lymph nodes. Ahn...
et al. [14] reported a case of prostate cancer in a 34-year-old man that initially presented with a diagnosis resembling lymphoma. This patient had bilateral supraclavicular lymph nodes with mediastinal, abdominal and pelvic disease. The patient had no urinary symptoms, a normal DRE, but a markedly elevated serum PSA concentration, bearing a marked resemblance to Case 3 in our series. Other authors have also reported sporadic cases and case series of prostate cancer metastasising to the lymph nodes with unusual presenting symptoms [15–17].

Not all enlarged nodes can be attributed to the presence of metastatic disease, as demonstrated by Young et al., who found the incidence of metastatic prostate carcinoma at staging lymphadenectomy to be a mere 4.6% [18].

Localized adenopathy should ideally prompt a search for an adjacent precipitating lesion and an examination of other nodal areas to rule out generalized lymphadenopathy. Most patients can be diagnosed based on a careful history and physical examination [19]. In many instances, as in the cases we present, the diagnosis may not be clinically evident at presentation. In our view, this should prompt biochemical analysis in addition to other investigations to reveal the nature of the enlarged adenopathy.

Whilst the patients in our case studies displayed no urinary symptoms, all three demonstrated the presence of enlarged lymph nodes and were presumed to have haematological malignancies. Prostatic malignancy was not considered at the outset. This resulted in a delayed diagnosis and a delay in definitive therapy.

We propose that prostate cancer should be considered as a differential when enlarged pelvic lymph nodes are found in male patients in the absence of another primary. A digital rectal examination and serum PSA estimation should be performed at an early stage in the patient’s management.

Author contributions
Nilu Malpani Dhoot, Maria luiza Yamada, Ramkumar S, contributed manuscript drafting and interpreted the image findings; Gamal Ghazala, Seyan Dattani reviewed the literature and contributed to the manuscript; Adam Levene performed the histological analysis of the surgical specimen. All authors issued the final approval for the version to be submitted.

Patient consent
We confirm that consent for publication has been obtained from the patient or his/her representatives.

Funding
Luton and Dunstable Hospital.

**REFERENCES**

[1] Wong SK, Mohamad NV, Giaze TR, Chin KY, Mohamed N, Ima-Nirwana S. Prostate cancer and bone metastases: the underlying mechanisms. Int J Mol Sci 2019;20(10):2587. Published 2019 May 27. doi:10.3390/ijms20102587.

[2] Gandaglia G, Abdullah F, Schifflmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 2014;74(2):210–16. Epub 2013 Oct 16. PMID: 24132735. doi:10.1002/pros.22742.

[3] Meijer HJ, Debas T, van Lin EN, Witjes JA, Kaanders JH, Barentsz JO, et al. A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured. Radiat Oncol 2013;8:190. doi:10.1186/1748-717X-8-190.

[4] Klassen Z. EAU 2020: Primary treatment of pelvic lymph node metastatic prostate cancer - surgery only. UroToday 2020. https://www.urotoday.com/conference-highlights/eauro-2020/prostate-cancer/123223-eau-2020-primary-treatment-of-pelvic-lymph-node-metastatic-prostate-cancer-surgery-only.html, (accessed date: 08/01/2022).

[5] National Institute for Health and Care Excellence (2021). Prostate cancer: Information about PSA testing. https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/psa-testing/, (accessed date: 08/01/2022).

[6] Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998 Oct 15;58(6):1513–20. PMID: 9803916.

[7] Cancer Research UK (2021). Prostate cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Four, (accessed date: 08/01/2022).

[8] Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91:66–73. 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9.0.CO;2-P.

[9] Lin HC, Chang TH, Li CC, Doreswamy K, Karthikeyan VS, Nagabhushana M, Shankaranand B, et al. Metastatic prostate cancer found incidentally during an inguinal herniorrhaphy: a case report. JTUA 2007;18:39–41.

[10] Tunio MA, Hashami A, Raza SS. Metastatic prostate adenocarcinoma presenting with bilateral inguinal adenopathy. J Surg Pak 2011;16:85–7.

[11] Paño S, Sebastià C, Buesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics 2011;31:135–60. doi:10.1148/rg.311105072.

[12] Saeter G, Fossa SD, Ous S, Blom GP, Kaalhus O. Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases. Br J Urol 1984;56:385–90.

[13] Platania M, Bajetta E, Guadalupi V, Buzzoni R, Colecchia M. Prostate adenocarcinoma presenting with supraclavicular node enlargement. Report of a case. Tumori 2008; 94:769–71.

[14] Ahn MJ, Oh SJ, Lee YY, Jung TJ, Kim IS, Choi IY, et al. A case of prostate cancer in 34-year-old man with generalized lymphadenopathy mimicking malignant lymphoma. J Korean Med Sci 1997;12:262–5.

[15] Cho K, Epstein J. Metastatic prostate carcinoma to supradiaphragmatic lymph nodes, a clinicopathologic and immunohistochemical study. Am J Surg Pathol 1987;11:457–63.

[16] Carleton J, van der Riet P, Dahm P. Metastatic prostate cancer presenting as an asymptomatic neck mass. Prostate Cancer Prostatic Dis 2005;8:293–5.
[17] Winstanley AM, Sandison A, Bott SR, Dogan A, Parkinson MC. Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002;55(8):623–6. doi:10.1136/jcp.55.8.623.

[18] Young MPA, Kirby RS, O’Donoghue EPN, Parkinson MC, et al. Accuracy and cost of intraoperative lymph node frozen section at radical prostatectomy. J Clin Pathol 1999;52:925–7 [PMC free article] [PubMed] [Google Scholar].

[19] Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998;58(6):1313–20 PMID: 9803196.